Biomissile
Biotech company developing first-in-class multi-specific antibodies using proprietary human domain antibody technology for diseases with unmet needs.
Private Company
Funding information not available
AI Company Overview
Biotech company developing first-in-class multi-specific antibodies using proprietary human domain antibody technology for diseases with unmet needs.
Technology Platform
Proprietary UDAB™ (fully human domain antibody) platform for discovering and developing bispecific and multispecific therapeutic antibodies with potential advantages in target engagement and reduced immunogenicity.
Opportunities
Risk Factors
Competitive Landscape
Competes with established players like Amgen, Roche, and emerging Chinese biotechs in multi-specific antibodies; differentiation depends on demonstrating clinical advantages of UDAB™ platform over existing technologies.